

# Ali T Taher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1684288/publications.pdf>

Version: 2024-02-01

479  
papers

14,326  
citations

24978

57  
h-index

34900

98  
g-index

481  
all docs

481  
docs citations

481  
times ranked

10341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Morbidity-free survival and hemoglobin level in non-transfusion-dependent $\beta^2$ -thalassemia: a 10-year cohort study. <i>Annals of Hematology</i> , 2022, 101, 203-204.	0.8	21
2	Psycho-oncology in the Arab world: The time is now. <i>Psycho-Oncology</i> , 2022, 31, 148-151.	1.0	3
3	Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?. <i>Blood Reviews</i> , 2022, 52, 100874.	2.8	6
4	Primary $\alpha$ -HBB gene mutation severity and long-term outcomes in a global cohort of $\beta^2$ -thalassaemia. <i>British Journal of Haematology</i> , 2022, 196, 414-423.	1.2	8
5	Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 93, 102641.	0.6	3
6	Clinical burden of hemophilia in older adults: Beyond bleeding risk. <i>Blood Reviews</i> , 2022, 53, 100912.	2.8	3
7	Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination. <i>Annals of Hematology</i> , 2022, 101, 1111-1113.	0.8	11
8	Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm. <i>Annals of Hematology</i> , 2022, , 1.	0.8	2
9	Inflammatory Bowel Disease: An Indication to Screen for Thrombophilia?. <i>Diseases (Basel)</i> , Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	1.0	1
10	Random Forest Clustering Identifies Three Subgroups of $\beta^2$ -Thalassemia with Distinct Clinical Severity. <i>Thalassemia Reports</i> , 2022, 12, 14-23.	0.1	3
11	Coronavirus Disease 2019 (COVID-19)- Associated central retinal vein occlusion: A case report and literature review. <i>Archives of Hematology Case Reports and Reviews</i> , 2022, 7, 009-012.	0.3	1
12	Risk of mortality from anemia and iron overload in nontransfusion-dependent $\beta^2$ -thalassemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	19
13	Redox Balance in $\beta^2$ -Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. <i>Antioxidants</i> , 2022, 11, 967.	2.2	5
14	An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with nontransfusion-dependent thalassemia (THETIS): 5-year results. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
15	Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS). <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
16	Pharmacological Induction of Fetal Hemoglobin in $\beta^2$ -Thalassemia and Sickle Cell Disease: An Updated Perspective. <i>Pharmaceuticals</i> , 2022, 15, 753.	1.7	14
17	Could Preoperative Unintended Weight Loss Predispose to Postoperative Thrombosis in Patients Undergoing Colorectal Cancer Surgery? An Analysis of the NSQIP Data. <i>Journal of the American College of Nutrition</i> , 2021, 40, 141-147.	1.1	3
18	A land in agony: COVID-19, economic collapse, political corruption, and a deadly blast. <i>American Journal of Hematology</i> , 2021, 96, E1-E2.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Management of non-transfusion-dependent $\beta^0$ -thalassemia (<sc>NTDT</sc>): The next 5 years. American Journal of Hematology, 2021, 96, E57-E59.	2.0	11
20	Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	2.0	28
21	$\beta^0$ -Thalassemias. New England Journal of Medicine, 2021, 384, 727-743.	13.9	183
22	CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of $\beta^0$ -Thalassemia through an Increase in 20-HETE Activity. International Journal of Molecular Sciences, 2021, 22, 1106.	1.8	6
23	Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence. Rheumatology and Therapy, 2021, 8, 81-94.	1.1	11
24	The use of luspatercept for thalassemia in adults. Blood Advances, 2021, 5, 326-333.	2.5	28
25	An Overview of Hepatocellular Carcinoma (HCC) in Lebanon: A Focus on Hepatitis B- and Thalassemia-Related HCC. , 2021, , 375-386.		0
26	Hepatocellular Carcinoma in Lebanon and Its Association with Thalassemia. , 2021, , 371-374.		0
27	Variations in hemoglobin level and morbidity burden in non-transfusion-dependent $\beta^0$ -thalassemia. Annals of Hematology, 2021, 100, 1903-1905.	0.8	20
28	COVID-19 pandemic and transfusion medicine: the worldwide challenge and its implications. Annals of Hematology, 2021, 100, 1115-1122.	0.8	20
29	Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS-CAT Study. Cancers, 2021, 13, 1033.	1.7	12
30	Antiphospholipid syndrome: the need for new international classification criteria. Expert Review of Clinical Immunology, 2021, 17, 385-394.	1.3	6
31	Intravenous immunoglobulin, neonatal alloimmune thrombocytopenia, and Sjogren's syndrome: A case report. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 258, 476-477.	0.5	4
32	Recommendations for pregnancy in Fanconi anemia. Expert Opinion on Biological Therapy, 2021, 21, 1-7.	1.4	2
33	Survival and causes of death in 2,033 patients with non-transfusion-dependent $\beta^0$ -thalassemia. Haematologica, 2021, 106, 2489-2492.	1.7	25
34	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent $\beta^0$ -thalassaemia. British Journal of Haematology, 2021, 194, 474-477.	1.2	10
35	<sc>SARS-CoV-2</sc> infection in patients with $\beta^0$ -thalassemia: Experience from <sc>Lebanon</sc>. American Journal of Hematology, 2021, 96, E285-E288.	2.0	3
36	Polymyalgia rheumatica-like presentation in a case of diffuse large B-cell lymphoma: a diagnostic pitfall. Journal of International Medical Research, 2021, 49, 030006052110185.	0.4	0

#	ARTICLE	IF	CITATIONS
37	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	1.8	21
38	Antiphospholipid antibodies and cerebrovascular thrombosis in the pediatric population: Few answers to many questions. <i>Lupus</i> , 2021, 30, 1365-1377.	0.8	0
39	The EHA Research Roadmap: Anemias. <i>HemaSphere</i> , 2021, 5, e607.	1.2	7
40	Implemented Interventions at the Naef K. Basile Cancer Institute to Protect Patients and Medical Personnel From COVID Infections: Effectiveness and Patient Satisfaction. <i>Frontiers in Oncology</i> , 2021, 11, 685107.	1.3	1
41	Abstract 56: Landscape and Challenges of Cancer Registration in the Middle East, North Africa and Turkey (MENAT). , 2021, , .		0
42	Digital thermography and vascular involvement in $\beta^2$ -thalassemia intermedia. <i>Annals of Hematology</i> , 2021, 100, 2471-2477.	0.8	1
43	Cancer Registration in the Middle East, North Africa, and Turkey: Scope and Challenges. <i>JCO Global Oncology</i> , 2021, 7, 1101-1109.	0.8	18
44	Henoch-Schönlein purpura: Another COVID-19 complication. <i>Pediatric Dermatology</i> , 2021, 38, 1359-1360.	0.5	19
45	Should we screen Eastern Mediterranean COVID-19 patients for inherited thrombophilia?. <i>Medical Hypotheses</i> , 2021, 152, 110621.	0.8	1
46	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in $\beta^2$ -thalassemia: current evidence and future clinical development. <i>Expert Review of Hematology</i> , 2021, 14, 633-644.	1.0	13
47	2021 update on clinical trials in $\beta^2$ -thalassemia. <i>American Journal of Hematology</i> , 2021, 96, 1518-1531.	2.0	38
48	Luspatercept for $\beta^2$ -thalassemia: beyond red blood cell transfusions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1363-1371.	1.4	14
49	Improving outcomes and quality of life for patients with transfusion-dependent $\beta^2$ -thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. <i>Expert Review of Hematology</i> , 2021, 14, 897-909.	1.0	13
50	The Lebanese healthcare sector: The point of exsanguination. <i>American Journal of Hematology</i> , 2021, 96, E403-E404.	2.0	1
51	COVID-19 vaccination immune response in patients with solid organ and haematologic malignancies: call for active monitoring. <i>Ecancermedicalscience</i> , 2021, 15, 1284.	0.6	1
52	Recommendations for diagnosis and treatment of methemoglobinemia. <i>American Journal of Hematology</i> , 2021, 96, 1666-1678.	2.0	56
53	Prevalence of thrombophilia-associated mutations and their clinical significance in a large cohort of Lebanese patients. <i>Meta Gene</i> , 2021, 29, 100936.	0.3	0
54	Assessment of Lebanese healthcare professionals' awareness on acquired haemophilia: a cross-sectional study. <i>Hematology</i> , 2021, 26, 83-87.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. <i>HemaSphere</i> , 2021, 5, e660.	1.2	1
56	Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent $\beta^2$ -Thalassemia in the BEYOND Trial. <i>Blood</i> , 2021, 138, 3081-3081.	0.6	4
57	Quality of life measures in Systemic Lupus Erythematosus: A systematic review. <i>Reumatismo</i> , 2021, 73, .	0.4	2
58	Effect of Perioperative Transfusion on Postoperative Morbidity Following Minimally Invasive Hysterectomy for Benign Indications. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 200-205.	0.3	7
59	The effect of anemia severity on postoperative morbidity among patients undergoing laparoscopic hysterectomy for benign indications. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 112-118.	1.3	12
60	No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet?. <i>Lancet Haematology</i> , 2020, 7, e429-e430.	2.2	0
61	Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 191, S50-S57.	0.8	13
62	A Report on the Education, Employment and Marital Status of Thalassemia Patients from a Tertiary Care Center in the Middle East. <i>Hemoglobin</i> , 2020, 44, 278-283.	0.4	4
63	Recommendations for Pregnancy in Rare Inherited Anemias. <i>HemaSphere</i> , 2020, 4, e446.	1.2	8
64	COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals. <i>Expert Review of Hematology</i> , 2020, 13, 1081-1092.	1.0	11
65	COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2020, 13, 117954412097866.	0.3	32
66	Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations. <i>American Journal of Hematology</i> , 2020, 95, E208-E210.	2.0	24
67	Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. <i>Drugs</i> , 2020, 80, 1053-1063.	4.9	49
68	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent $\beta^2$ -Thalassemia. <i>New England Journal of Medicine</i> , 2020, 382, 1219-1231.	13.9	177
69	Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 79-89.	0.5	1
70	Thalassemia in the emergency department: special considerations for a rare disease. <i>Annals of Hematology</i> , 2020, 99, 1967-1977.	0.8	9
71	Less "reds"™ more "blues"™: hemoglobin level and depression in non-transfusion-dependent thalassemia. <i>Annals of Hematology</i> , 2020, 99, 903-904.	0.8	9
72	MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. <i>Cancer Medicine</i> , 2020, 9, 4512-4526.	1.3	39

#	ARTICLE	IF	CITATIONS
73	Emerging therapies in $\beta^2$ -thalassemia: toward a new era in management. Expert Opinion on Emerging Drugs, 2020, 25, 113-122.	1.0	12
74	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	0.6	7
75	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with $\beta^2$ -Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	0.6	8
76	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in $\beta^2$ -Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	0.6	8
77	Recurrent <i>Campylobacter</i> Bacteremia as the First Manifestation of Hypogammaglobulinemia: A Case Report and Literature Review. Infection and Chemotherapy, 2020, 52, 415.	1.0	7
78	Disparities in the risk of septic events in patients undergoing splenectomy for hematological malignancies (D $\text{\u00c0}$ ROSE $\text{\u00e0}$ PUSH): A study based on ACS $\text{\u00e0}$ NSQIP database. American Journal of Hematology, 2019, 94, E205-E207.	2.0	0
79	Quality of life in patients with $\beta^2$ -thalassemia: A prospective study of transfusion $\text{\u00e0}$ dependent and non $\text{\u00e0}$ transfusion $\text{\u00e0}$ dependent patients in Greece, Italy, Lebanon, and Thailand. American Journal of Hematology, 2019, 94, E261-E264.	2.0	21
80	Structure and evaluation of a residency research program in a university hospital. BMC Medical Education, 2019, 19, 406.	1.0	5
81	Influence of patient $\text{\u00e0}$ reported outcomes on the treatment effect of deferasirox film $\text{\u00e0}$ coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. American Journal of Hematology, 2019, 94, E96-E99.	2.0	5
82	Bariatric venous thromboembolism prophylaxis: an update on the literature. Expert Review of Hematology, 2019, 12, 763-771.	1.0	23
83	Thalassemia and malignancy: An emerging concern?. Blood Reviews, 2019, 37, 100585.	2.8	18
84	Development of a thalassemia $\text{\u00e0}$ related thrombosis risk scoring system. American Journal of Hematology, 2019, 94, E207-E209.	2.0	7
85	Cardiac involvement in beta-thalassaemia: current treatment strategies. Postgraduate Medicine, 2019, 131, 261-267.	0.9	13
86	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	1.2	13
87	Development of a patient $\text{\u00e0}$ reported outcomes symptom measure for patients with nontransfusion $\text{\u00e0}$ dependent thalassemia (NTDT $\text{\u00e0}$ PRO $\text{\u00c2}$ <sup>©</sup> ). American Journal of Hematology, 2019, 94, 171-176.	2.0	7
88	Validation of a patient $\text{\u00e0}$ reported outcomes symptom measure for patients with nontransfusion $\text{\u00e0}$ dependent thalassemia (NTDT $\text{\u00e0}$ PRO $\text{\u00c2}$ <sup>©</sup> ). American Journal of Hematology, 2019, 94, 177-183.	2.0	7
89	Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion $\text{\u00e0}$ dependent thalassemia. American Journal of Hematology, 2019, 94, E43-E45.	2.0	10
90	Sotatercept, a novel transforming growth factor $\beta^2$ ligand trap, improves anemia in $\beta^2$ -thalassemia: a phase II, open-label, dose-finding study. Haematologica, 2019, 104, 477-484.	1.7	61

#	ARTICLE	IF	CITATIONS
91	Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study. American Journal of Hematology, 2019, 94, E15-E17.	2.0	2
92	Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes. Annals of Hematology, 2019, 98, 833-840.	0.8	0
93	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood, 2019, 134, 2245-2245.	0.6	7
94	Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 3545-3545.	0.6	3
95	<scp>MRI</scp> for the diagnosis of cardiac and liver iron overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited. American Journal of Hematology, 2018, 93, E135-E137.	2.0	14
96	Hepatocellular Carcinoma in a $\beta^2$ -Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin, 2018, 42, 58-60.	0.4	7
97	Microcytosis is important in screening of iron deficiency anemia. European Journal of Internal Medicine, 2018, 48, e39.	1.0	0
98	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews, 2018, 32, 300-311.	2.8	95
99	Hypercoagulability and Vascular Disease. Hematology/Oncology Clinics of North America, 2018, 32, 237-245.	0.9	20
100	Emerging Therapies. Hematology/Oncology Clinics of North America, 2018, 32, 343-352.	0.9	5
101	Clinical Complications and Their Management. Hematology/Oncology Clinics of North America, 2018, 32, 223-236.	0.9	14
102	Ineffective Erythropoiesis: Anemia and Iron Overload. Hematology/Oncology Clinics of North America, 2018, 32, 213-221.	0.9	54
103	Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, xv-xvi.	0.9	5
104	Rheumatological complications of beta-thalassaemia: an overview. Rheumatology, 2018, 57, 19-27.	0.9	16
105	Thalassaemia. Lancet, The, 2018, 391, 155-167.	6.3	512
106	Iron deficiency beyond erythropoiesis: should we be concerned?. Current Medical Research and Opinion, 2018, 34, 81-93.	0.9	83
107	Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood, 2018, 131, 263-265.	0.6	45
108	Iron overload and chelation therapy in hemoglobinopathies. Thalassemia Reports, 2018, 8, .	0.1	0

#	ARTICLE	IF	CITATIONS
109	DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2018, 10, e2018066.	0.5	12
110	Ovarian teratoma: yet another cause of immune thrombocytopenia. International Journal of Women's Health, 2018, Volume 10, 567-570.	1.1	0
111	Hepatocellular Carcinoma in $\hat{\beta}^2$ -Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. International Journal of Molecular Sciences, 2018, 19, 4070.	1.8	25
112	Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health and Quality of Life Outcomes, 2018, 16, 216.	1.0	15
113	Renal Complications in Thalassemia. Thalassemia Reports, 2018, 8, 7481.	0.1	9
114	Triple thrombophilic simultaneous mutations in patients after bariatric surgery: is there a role for screening in the Eastern Mediterranean?. Journal of Surgical Case Reports, 2018, 2018, rjy135.	0.2	0
115	How I manage medical complications of $\hat{\beta}^2$ -thalassemia in adults. Blood, 2018, 132, 1781-1791.	0.6	78
116	Assessment and study of knowledge and practice across different settings in Lebanon based on the recommendations of the American Society of Hematology <i>Choosing Wisely</i> campaign (ASKâ€PADS) Tj ETQq00 0 rgBT/Overlock	0.0	0
117	The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Review of Hematology, 2018, 11, 487-494.	1.0	1
118	Drug related bleeding as a cause of emergency department visits; a Lebanese tertiary care center experience. European Journal of Internal Medicine, 2018, 55, e10-e12.	1.0	0
119	Could sodium imbalances predispose to postoperative venous thromboembolism? An analysis of the NSQIP database. Thrombosis Journal, 2018, 16, 11.	0.9	11
120	Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. International Journal of Molecular Sciences, 2018, 19, 182.	1.8	46
121	Impact and management of iron deficiency and iron deficiency anemia in womenâ€™s health. Expert Review of Hematology, 2018, 11, 727-736.	1.0	70
122	Iron overload in patients with myelodysplastic syndromes: An updated overview. Cancer, 2018, 124, 3979-3989.	2.0	24
123	Optimising management of deferasirox therapy for patients with transfusionâ€dependent thalassaemia and lowerâ€risk myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 272-282.	1.1	16
124	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	0.6	11
125	Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. Blood, 2018, 132, 2336-2336.	0.6	5
126	Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry. Blood, 2018, 132, 5461-5461.	0.6	1

#	ARTICLE	IF	CITATIONS
127	GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia. <i>Blood</i> , 2018, 132, 3633-3633.	0.6	0
128	Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry. <i>Blood</i> , 2018, 132, 4311-4311.	0.6	4
129	Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia. <i>Blood</i> , 2018, 132, 3635-3635.	0.6	2
130	Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. <i>Cancer</i> , 2017, 123, 1073-1073.	2.0	1
131	Anemia in the elderly: a consequence of aging?. <i>Expert Review of Hematology</i> , 2017, 10, 327-335.	1.0	57
132	Outcomes of Laparoscopic vs Open Common Bile Duct Exploration: Analysis of the NSQIP Database. <i>Journal of the American College of Surgeons</i> , 2017, 224, 833-840e2.	0.2	18
133	Pregnancy in $\beta$ -thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes. <i>American Journal of Hematology</i> , 2017, 92, E96-E99.	2.0	6
134	New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. <i>American Journal of Hematology</i> , 2017, 92, 420-428.	2.0	66
135	Hematologic malignancies in thalassemia: Adding new cases to the repertoire. <i>American Journal of Hematology</i> , 2017, 92, E68-E70.	2.0	6
136	A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits. <i>American Journal of Hematology</i> , 2017, 92, 414-416.	2.0	11
137	Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. <i>Cancer</i> , 2017, 123, 751-758.	2.0	54
138	Iron overload across the spectrum of nontransfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. <i>British Journal of Haematology</i> , 2017, 176, 288-299.	1.2	43
139	Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. <i>European Journal of Internal Medicine</i> , 2017, 42, 16-23.	1.0	76
140	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. <i>Oncologist</i> , 2017, 22, 1222-1231.	1.9	167
141	Revisiting beta thalassemia intermedia: past, present, and future prospects. <i>Hematology</i> , 2017, 22, 607-616.	0.7	19
142	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	2.0	290
143	Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients. <i>Annals of Hematology</i> , 2017, 96, 597-603.	0.8	9
144	Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. <i>American Journal of Hematology</i> , 2017, 92, E35-E37.	2.0	13

#	ARTICLE	IF	CITATIONS
145	Safety and pharmacokinetics of the oral iron chelator SP420 in $\beta^0$ -thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	2.0	10
146	Causes of hospital admission in $\beta^0$ -thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center. American Journal of Hematology, 2017, 92, E652-E653.	2.0	1
147	Novel mutation in the Transferrin receptor-2 in a patient with Hereditary Hemochromatosis type 3. Meta Gene, 2017, 14, 30-32.	0.3	1
148	Insights into the diagnosis and management of iron deficiency in inflammatory bowel disease. Expert Review of Hematology, 2017, 10, 801-808.	1.0	17
149	Low utility of lower extremity ultrasound prior to application of sequential compression device in critically ill adults. Vascular Medicine, 2017, 22, 66-68.	0.8	0
150	Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassaemias "response to Angiotensin II". British Journal of Haematology, 2017, 176, 989-990.	1.2	1
151	One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, 188-196.	0.8	24
152	Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. European Journal of Haematology, 2017, 98, 280-288.	1.1	29
153	Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Hemoglobin, 2017, 41, 267-273.	0.4	6
154	Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. International Journal of Molecular Sciences, 2017, 18, 2778.	1.8	20
155	Iron overload in thalassemia: different organs at different rates. Hematology American Society of Hematology Education Program, 2017, 2017, 265-271.	0.9	167
156	Quality of Life in Patients with $\beta^0$ -Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent. Blood, 2017, 130, 751-751.	0.6	1
157	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	2.0	15
158	Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs, 2016, 4, 677-686.	0.5	2
159	Morbidities in non-transfusion-dependent thalassemia. Annals of the New York Academy of Sciences, 2016, 1368, 82-94.	1.8	20
160	Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database. Journal of the American College of Surgeons, 2016, 222, 30-40.	0.2	56
161	Cortical bone invasion in non-transfusion-dependent thalassemia: tumefactive extramedullary hematopoiesis reviewed. Radiologia Medica, 2016, 121, 626-634.	4.7	0
162	Deferasirox in thalassemia patients with end-stage renal disease. American Journal of Hematology, 2016, 91, E456-7.	2.0	5

#	ARTICLE	IF	CITATIONS
163	Immune thrombocytopenia: a comprehensive review from pathophysiology to promising treatment modalities. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1217-1227.	0.5	2
164	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 23-29.	0.6	24
165	Clinical monitoring and management of complications related to chelation therapy in patients with $\beta^2$ -thalassemia. <i>Expert Review of Hematology</i> , 2016, 9, 151-168.	1.0	23
166	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. <i>European Journal of Internal Medicine</i> , 2016, 28, 91-96.	1.0	14
167	Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 301-311.	1.0	22
168	New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study. <i>Blood</i> , 2016, 128, 1285-1285.	0.6	4
169	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinentall Collaborative Study. <i>Blood</i> , 2016, 128, 3633-3633.	0.6	15
170	Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study. <i>Blood</i> , 2016, 128, 850-850.	0.6	5
171	Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study. <i>Blood</i> , 2016, 128, 852-852.	0.6	10
172	Comment on "deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial". <i>American Journal of Hematology</i> , 2015, 90, E192-3.	2.0	1
173	Iron overload in transfusion-dependent thalassemia. <i>Hematology</i> , 2015, 20, 311-312.	0.7	7
174	Post-Partum Ovarian Vein Thrombosis: Combined Effect of Infection and Factor V Leiden Mutation. <i>Turkish Journal of Haematology</i> , 2015, 32, 80-81.	0.2	0
175	Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. <i>Journal of Blood Medicine</i> , 2015, 6, 197.	0.7	63
176	Chronic lymphocytic leukemia of the genital tract. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 126.	0.5	3
177	Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 108-109.	0.6	20
178	Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2015, 168, 284-290.	1.2	50
179	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. <i>British Journal of Haematology</i> , 2015, 169, 887-898.	1.2	22
180	Globin gene regulation for treating $\beta^2$ -thalassemias: progress, obstacles and future. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1047-1062.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Thalassaemia in children: from quality of care to quality of life. Archives of Disease in Childhood, 2015, 100, 1051-1057.	1.0	22
182	Venous thromboembolism and preoperative steroid use: Analysis of the NSQIP database to evaluate risk in surgical patients. European Journal of Internal Medicine, 2015, 26, 528-533.	1.0	18
183	Efficacy and Safety of Deferasirox Across Underlying Non-Transfusion-Dependent Thalassemia Syndromes: 1-Year Results from the Thetis Study. Blood, 2015, 126, 3366-3366.	0.6	0
184	Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study. Blood, 2015, 126, 4570-4570.	0.6	1
185	Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study. Blood, 2015, 126, 2153-2153.	0.6	7
186	Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 166-169.	0.6	15
187	Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet Journal of Rare Diseases, 2014, 9, 131.	1.2	30
188	Î²-Thalassemia Intermedia: A Bird's-Eye View. Turkish Journal of Haematology, 2014, 31, 5-16.	0.2	33
189	Novel Approach to Reactive Oxygen Species in Nontransfusion-Dependent Thalassemia. BioMed Research International, 2014, 2014, 1-8.	0.9	17
190	A killer revealed: 10-year experience with beta-thalassemia intermedia. Hematology, 2014, 19, 196-198.	0.7	7
191	Association between cardiac T2* magnetic resonance imaging values and endocrine function tests in patients with Î²-thalassemia major. Blood Cells, Molecules, and Diseases, 2014, 52, 50-51.	0.6	1
192	Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2014, 91, 64-73.	2.0	46
193	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism: Evidence From Major Clinical Trials. Seminars in Hematology, 2014, 51, 121-130.	1.8	9
194	An overview of current treatment strategies for Î²-thalassemia. Expert Opinion on Orphan Drugs, 2014, 2, 665-679.	0.5	8
195	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	0.6	8
196	Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. European Journal of Haematology, 2014, 92, 521-526.	1.1	17
197	Multicenter validation of spin-density projection-assisted R2* MRI for the noninvasive measurement of liver iron concentration. Magnetic Resonance in Medicine, 2014, 71, 2215-2223.	1.9	100
198	Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide. Drugs, 2014, 74, 1719-1729.	4.9	10

#	ARTICLE	IF	CITATIONS
199	Guidelines for Diagnosis and Management of Beta-Thalassemia Intermedia. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 583-596.	0.3	61
200	Priapism, an Emerging Complication in $\hat{I}^2$ -Thalassemia Intermedia Patients. <i>Hemoglobin</i> , 2014, 38, 351-354.	0.4	7
201	Preventing Thalassemia in Lebanon: Successes and Challenges in a Developing Country. <i>Hemoglobin</i> , 2014, 38, 308-311.	0.4	13
202	Serum ferritin level and morbidity risk in transfusion-independent patients with $\hat{A}$ -thalassemia intermedia: the ORIENT study. <i>Haematologica</i> , 2014, 99, e218-e221.	1.7	56
203	Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox â€“ a Post-Hoc Analysis from the Epic Study. <i>Blood</i> , 2014, 124, 52-52.	0.6	4
204	An Update on Thalassemia Intermedia. <i>Journal Medical Libanais</i> , 2014, 61, 175-182.	0.0	10
205	Relative Trends in Myocardial T2* Versus Myocardial Iron Concentration As Representations of Myocardial Iron Chelation Efficacy in Patients with $\hat{I}^2$ Thalassemia Major Treated with Deferasirox for up to 3 Years. <i>Blood</i> , 2014, 124, 4040-4040.	0.6	0
206	Venous Thromboembolism and Preoperative Steroid Use, a Retrospective Cohort Study from the ACS-NSQIP Database: Are Surgical Patients at Risk?. <i>Blood</i> , 2014, 124, 2865-2865.	0.6	1
207	Non-Transfusion Dependent Thalassemia: Translating Evidence to Guidelines. <i>Thalassemia Reports</i> , 2014, 4, 16-24.	0.1	0
208	The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 81-82.	1.0	12
209	Treating iron overload in patients with nonâ€“transfusionâ€“dependent thalassemia. <i>American Journal of Hematology</i> , 2013, 88, 409-415.	2.0	67
210	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. <i>Annals of Hematology</i> , 2013, 92, 1485-1493.	0.8	64
211	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 38.	1.6	47
212	Deferasirox demonstrates a doseâ€“dependent reduction in liver iron concentration and consistent efficacy across subgroups of nonâ€“transfusionâ€“dependent thalassemia patients. <i>American Journal of Hematology</i> , 2013, 88, 503-506.	2.0	16
213	Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. <i>Expert Review of Hematology</i> , 2013, 6, 495-509.	1.0	9
214	End stage renal disease in six patients with beta-thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 146-148.	0.6	8
215	Deferiprone-induced seizures in a patient with $\hat{I}^2$ -thalassemia major. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 94-95.	0.6	3
216	Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with $\hat{I}^2$ -thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 35-38.	0.6	47

#	ARTICLE	IF	CITATIONS
217	Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 747-748, 40-47.	0.4	24
218	Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases. <i>Turkish Journal of Haematology</i> , 2013, 30, 184-187.	0.2	1
219	Iron overload in $\beta^2$ -thalassemia intermedia. <i>Current Opinion in Hematology</i> , 2013, 20, 187-192.	1.2	42
220	A liver mass in an iron-overloaded thalassaemia intermedia patient. <i>British Journal of Haematology</i> , 2013, 161, 1-1.	1.2	8
221	A randomized phase I/II trial of $\beta$ -HQB1001, an oral fetal globin gene inducer, in $\beta^2$ -thalassaemia intermedia and $\beta$ -HbE $\beta^2$ -thalassaemia. <i>British Journal of Haematology</i> , 2013, 161, 587-593.	1.2	31
222	Approaches to management of beta-thalassemia intermedia. <i>Thalassemia Reports</i> , 2013, 3, 12.	0.1	0
223	Glomerular Hyperfiltration and Proteinuria in Transfusion-Independent Patients with $\beta^2$ -Thalassemia Intermedia. <i>Nephron</i> , 2013, 121, c136-c143.	0.9	31
224	Clinical experience with fetal hemoglobin induction therapy in patients with $\beta^2$ -thalassemia. <i>Blood</i> , 2013, 121, 2199-2212.	0.6	154
225	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. <i>Haematologica</i> , 2013, 98, 1359-1367.	1.7	40
226	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. <i>Annals of Hepatology</i> , 2013, 12, 142-146.	0.6	46
227	Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. <i>Blood</i> , 2013, 122, 1016-1016.	0.6	3
228	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. <i>Blood Transfusion</i> , 2013, 11, 108-22.	0.3	17
229	Potential mechanisms for renal damage in beta-thalassemia. <i>Journal of Nephrology</i> , 2013, 26, 821-828.	0.9	22
230	A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent $\beta^2$ -Thalassemia. <i>Blood</i> , 2013, 122, 2261-2261.	0.6	0
231	Outcome Of Bone Marrow Transplantation In Lebanese Children With $\beta^2$ -Thalassemia Major. <i>Blood</i> , 2013, 122, 5505-5505.	0.6	0
232	Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. <i>Annals of Hepatology</i> , 2013, 12, 142-6.	0.6	18
233	Mechanisms of Renal Disease in $\beta^2$ -Thalassemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1299-1302.	3.0	58
234	Frequency of Triple Mutations Involving Factor V, Prothrombin, and Methylenetetrahydrofolate Reductase Genes Among Patients Referred for Molecular Thrombophilia Workup in a Tertiary Care Center in Lebanon. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 223-225.	0.3	6

#	ARTICLE	IF	CITATIONS
235	Â-Thalassemia Intermedia: A Clinical Perspective. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a013482-a013482.	2.9	102
236	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with Â-thalassemia major. Haematologica, 2012, 97, 842-848.	1.7	122
237	Â-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. Anemia, 2012, 2012, 1-1.	0.5	38
238	Prevalence of Depression and Anxiety in Adult Patients with Â-Thalassemia Major and Intermedia. International Journal of Psychiatry in Medicine, 2012, 44, 291-303.	0.8	24
239	The Spine in Â-Thalassemia Syndromes. Spine, 2012, 37, 334-339.	1.0	27
240	A new chelator in the house. Blood, 2012, 119, 3191-3192.	0.6	1
241	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, 120, 970-977.	0.6	115
242	How I treat transfusional iron overload. Blood, 2012, 120, 3657-3669.	0.6	168
243	Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S1-S2.	2.8	13
244	Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews, 2012, 26, S16-S19.	2.8	105
245	Hypercoagulability in non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S20-S23.	2.8	44
246	Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Reviews, 2012, 26, S24-S27.	2.8	40
247	Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin. Journal of Thrombosis and Thrombolysis, 2012, 34, 541-544.	1.0	9
248	Hematological manifestations of celiac disease. Scandinavian Journal of Gastroenterology, 2012, 47, 1401-1411.	0.6	45
249	Mondor's Disease of the Breast in the Context of Inherited Thrombophilia. Breast Journal, 2012, 18, 373-374.	0.4	2
250	Carbamazepine-induced thrombocytopenia. Blood Cells, Molecules, and Diseases, 2012, 48, 197-198.	0.6	8
251	Hypercoagulability in Â-thalassemia: a status quo. Expert Review of Hematology, 2012, 5, 505-512.	1.0	70
252	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with Â-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2012, 49, 136-139.	0.6	42

#	ARTICLE	IF	CITATIONS
253	Cerebral infarction in $\hat{\imath}^2$ -thalassemia intermedia: Breaking the silence. <i>Thrombosis Research</i> , 2012, 130, 695-702.	0.8	81
254	Fetal hemoglobin levels and morbidity in untransfused patients with $\hat{\imath}^2$ -thalassemia intermedia. <i>Blood</i> , 2012, 119, 364-367.	0.6	85
255	Serum ferritin levels and endocrinopathy in medically treated patients with $\hat{\imath}^2$ thalassemia major. <i>Annals of Hematology</i> , 2012, 91, 1107-1114.	0.8	79
256	Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment. <i>International Wound Journal</i> , 2012, 9, 344-347.	1.3	11
257	Brain positron emission tomography in splenectomized adults with $\hat{\imath}^2$ -thalassemia intermedia: uncovering yet another covert abnormality. <i>Annals of Hematology</i> , 2012, 91, 235-241.	0.8	27
258	Serum Ferritin Levels and Morbidity in $\hat{\imath}^2$ -Thalassemia Intermedia: A 10-Year Cohort Study. <i>Blood</i> , 2012, 120, 1021-1021.	0.6	11
259	Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in $\hat{\imath}^2$ -Thalassemia Intermedia. <i>Blood</i> , 2012, 120, 1024-1024.	0.6	1
260	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). <i>Blood</i> , 2012, 120, 3258-3258.	0.6	3
261	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. <i>Blood</i> , 2012, 120, 2122-2122.	0.6	1
262	Predicting venous thromboembolism in hospitalized medical patients: are we there yet?. <i>Expert Review of Hematology</i> , 2011, 4, 1-3.	1.0	3
263	THALASSEMIA AND VENOUS THROMBOEMBOLISM. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011025.	0.5	39
264	Thrombosis in Thalassemia: Why are we so Concerned?. <i>Hemoglobin</i> , 2011, 35, 503-510.	0.4	40
265	Bone disease and skeletal complications in patients with $\hat{\imath}^2$ thalassemia major. <i>Bone</i> , 2011, 48, 425-432.	1.4	127
266	Risk factors for pulmonary hypertension in patients with $\hat{\imath}^2$ thalassemia intermedia. <i>European Journal of Internal Medicine</i> , 2011, 22, 607-610.	1.0	56
267	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with $\hat{\imath}^2$ thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 232-234.	0.6	55
268	Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. <i>Lancet, The</i> , 2011, 378, 1396-1407.	6.3	1,007
269	Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. <i>Haematologica</i> , 2011, 96, e5-e6.	1.7	6
270	Optimal management of $\hat{\imath}^2$ thalassaemia intermedia. <i>British Journal of Haematology</i> , 2011, 152, 512-523.	1.2	187

#	ARTICLE	IF	CITATIONS
271	Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. <i>European Journal of Haematology</i> , 2011, 87, 73-79.	1.1	39
272	Response of iron overload to deferasirox in rare transfusionâ€dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. <i>European Journal of Haematology</i> , 2011, 87, 338-348.	1.1	28
273	Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with $\beta^2$ -thalassaemia: results from the ESCALATOR study. <i>European Journal of Haematology</i> , 2011, 87, 349-354.	1.1	12
274	Importance of optimal dosing $\approx 30$ â€fmg/kg/d during deferasirox treatment: 2.7â€yr followâ€up from the ESCALATOR study in patients with $\beta^2$ -thalassaemia. <i>European Journal of Haematology</i> , 2011, 87, 355-365.	1.1	31
275	Brain magnetic resonance angiography in splenectomized adults with $\beta^2$ -thalassemia intermedia. <i>European Journal of Haematology</i> , 2011, 87, 539-546.	1.1	46
276	How long should we delay hip fracture surgery for elderly patients on clopidogrel?. <i>Injury</i> , 2011, 42, 1509-1510.	0.7	7
277	The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 47-56.	1.0	29
278	Transfusion-related Plasmodium ovale malaria complicated by acute respiratory distress syndrome (ARDS) in a non-endemic country. <i>Parasitology International</i> , 2011, 60, 114-116.	0.6	22
279	Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1418-1428.	1.0	33
280	Elevated liver iron concentration is a marker of increased morbidity in patients with $\beta^2$ thalassemia intermedia. <i>Haematologica</i> , 2011, 96, 1605-1612.	1.7	153
281	<i>JAK2 V617F</i> Gene Mutation in the Laboratory Work-Up of Myeloproliferative Disorders: Experience of a Major Referral Center in Lebanon. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 263-265.	0.3	20
282	Continued improvement in myocardial T2* over two years of deferasirox therapy in $\beta^2$ -thalassemia major patients with cardiac iron overload. <i>Haematologica</i> , 2011, 96, 48-54.	1.7	70
283	ANTITHROMBOTIC PROPHYLAXIS IN THE MIDDLE EAST. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011023.	0.5	2
284	Iron Chelation Therapy for Transfusional Iron Overload: A Swift Evolution. <i>Hemoglobin</i> , 2011, 35, 565-573.	0.4	10
285	Relationship Between Total Iron Removed by Phlebotomy and Iron Removed From the Liver in Pediatric Thalassemia Major Patients Following Curative Stem Cell Transplant. <i>Blood</i> , 2011, 118, 5300-5300.	0.6	1
286	Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study. <i>Blood</i> , 2011, 118, 902-902.	0.6	2
287	The role of liver iron in hepatitis C antiviral treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 769.	0.8	1
288	Efficacy of deferasirox in reducing and preventing cardiac iron overload in $\beta^2$ -thalassemia. <i>Blood</i> , 2010, 115, 2364-2371.	0.6	168

#	ARTICLE	IF	CITATIONS
289	Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. <i>Blood</i> , 2010, 115, 2980-2981.	0.6	27
290	Covert brain ischaemia in splenectomised adults with thalassemia intermedia: An emerging entity. <i>Thrombosis and Haemostasis</i> , 2010, 104, 652-653.	1.8	4
291	Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with $\beta^2$ -thalassemia major. <i>Annals of Hematology</i> , 2010, 89, 405-409.	0.8	53
292	Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. <i>Annals of Hematology</i> , 2010, 89, 585-589.	0.8	55
293	Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome. <i>Rheumatology International</i> , 2010, 30, 993-994.	1.5	0
294	Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. <i>European Spine Journal</i> , 2010, 19, 871-878.	1.0	164
295	Primary colorectal lymphoma. <i>Medical Oncology</i> , 2010, 27, 249-254.	1.2	18
296	Malignancy and hypercoagulability: a two-way association revisited. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 340-341.	1.0	2
297	The wanderer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 662.e1.	0.7	1
298	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <i>American Journal of Hematology</i> , 2010, 85, 288-290.	2.0	61
299	Iron chelation therapy for patients with sickle cell disease and iron overload. <i>American Journal of Hematology</i> , 2010, 85, 782-786.	2.0	15
300	Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 54-59.	1.9	72
301	Age-related complications in treatment-naïve patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2010, 150, 486-489.	1.2	100
302	Redefining thalassemia as a hypercoagulable state. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 231-236.	1.8	78
303	JAK2V617F and Prothrombin G20210A Gene Mutations in a Patient With Budd-Chiari Syndrome and Essential Thrombocythemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 472-474.	0.7	2
304	Massive Pulmonary Embolism Associated With Factor V Leiden, Prothrombin, and Methylenetetrahydrofolate Reductase Gene Mutations in a Young Patient on Oral Contraceptive Pills: A Case Report. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 594-598.	0.7	5
305	Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with $\beta^2$ -Thalassemia: Results from the ESCALATOR Trial. <i>Acta Haematologica</i> , 2010, 123, 220-225.	0.7	43
306	Use of Recombinant Activated Factor VII for Intractable Bleeding in Patients Without Hemophilia: A Developing Country Tertiary Care Center's Experience. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 658-662.	0.7	0

#	ARTICLE	IF	CITATIONS
307	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. <i>Haematologica</i> , 2010, 95, 557-566.	1.7	260
308	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. <i>Blood</i> , 2010, 115, 1886-1892.	0.6	315
309	Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the Tj ETQq1 1 0.784314 rgBT /Overloc	0.9	7
310	A closer look at paroxysmal nocturnal hemoglobinuria. <i>European Journal of Internal Medicine</i> , 2010, 21, 260-267.	1.0	23
311	A computed tomography Iron Index. <i>European Journal of Radiology</i> , 2010, 75, 189-190.	1.2	0
312	Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration. <i>Blood</i> , 2010, 116, 2053-2053.	0.6	2
313	Continued Improvement and Normalization of Myocardial T2* In Patients with $\beta^2$ -thalassemia Major Treated with Deferasirox (Exjade <sup>®</sup> ) for up to 3 Years. <i>Blood</i> , 2010, 116, 4276-4276.	0.6	8
314	Risk Factors for Pulmonary Hypertension In Patients with Thalassemia Intermedia. <i>Blood</i> , 2010, 116, 2069-2069.	0.6	0
315	Update on the use of deferasirox in the management of iron overload. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 857.	0.9	27
316	Aspirin Resistance. <i>Advances in Hematology</i> , 2009, 2009, 1-10.	0.6	32
317	Antiphospholipid Syndrome, Microalbuminuria, and Risk of Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 945.	3.8	1
318	Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. <i>Lupus</i> , 2009, 18, 845-847.	0.8	23
319	Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. <i>Oncologist</i> , 2009, 14, 489-496.	1.9	17
320	Re: Anti-Angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1657-1657.	3.0	0
321	Myocardial Infarction in a 28-Year-Old Thalassemia Intermedia Patient. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 467-469.	0.7	3
322	Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with $\beta^2$ -thalassaemia. <i>European Journal of Haematology</i> , 2009, 82, 454-457.	1.1	70
323	Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with $\beta^2$ -thalassaemia: the ESCALATOR study. <i>European Journal of Haematology</i> , 2009, 82, 458-465.	1.1	131
324	Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. <i>European Journal of Haematology</i> , 2009, 83, 565-571.	1.1	33

#	ARTICLE	IF	CITATIONS
325	The impact of inherited thrombophilia on surgery: A factor to consider before transplantation?. <i>Molecular Biology Reports</i> , 2009, 36, 1041-1051.	1.0	20
326	Absence of JAK2 V617F mutation in thalassemia intermedia patients. <i>Molecular Biology Reports</i> , 2009, 36, 1555-1557.	1.0	10
327	The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon. <i>Rheumatology International</i> , 2009, 29, 1255-1257.	1.5	1
328	Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?. <i>Annals of Hematology</i> , 2009, 88, 1033-1034.	0.8	9
329	Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. <i>Annals of Hematology</i> , 2009, 88, 1263-1264.	0.8	8
330	Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2009, 146, 569-572.	1.2	66
331	Pregnancy and risk of venous thromboembolism in developing countries. <i>British Journal of Haematology</i> , 2009, 146, 691-692.	1.2	0
332	Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. <i>British Journal of Haematology</i> , 2009, 147, 634-640.	1.2	71
333	Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. <i>British Journal of Haematology</i> , 2009, 147, 752-759.	1.2	101
334	Effects of divalproex sodium on hemoglobin level. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 49-52.	0.6	3
335	Differences in response to fetal hemoglobin induction therapy in $\beta^0$ -thalassemia and sickle cell disease. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 58-62.	0.6	19
336	Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. <i>Thrombosis Research</i> , 2009, 123, 679-686.	0.8	53
337	Ventricular late potentials among thalassemia patients. <i>International Journal of Cardiology</i> , 2009, 132, 453-455.	0.8	20
338	Thalassaemia Intermedia: an Update. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009004.	0.5	34
339	Iron Overload: Consequences, Assessment, and Monitoring. <i>Hemoglobin</i> , 2009, 33, S46-S57.	0.4	59
340	Severe hemophagocytic syndrome developing after treatment initiation for disseminated <i>Mycobacterium tuberculosis</i> : Case report and literature review. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 535-537.	1.5	9
341	An Electronic Infrastructure for Research and Treatment of the Thalassemias and Other Hemoglobinopathies: The Euro-Mediterranean Ithamet Project. <i>Hemoglobin</i> , 2009, 33, 163-176.	0.4	23
342	Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. <i>Hemoglobin</i> , 2009, 33, S145-S159.	0.4	33

#	ARTICLE	IF	CITATIONS
343	Current Understanding in the Management of Sickle Cell Disease. Hemoglobin, 2009, 33, S107-S115.	0.4	12
344	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. Hemoglobin, 2009, 33, S58-S69.	0.4	33
345	The Hypercoagulable State in Thalassemia Intermedia. Hemoglobin, 2009, 33, S160-S169.	0.4	16
346	Recombinant Activated Factor VII in Abdominal Aortic Emergencies. Annals of Surgery, 2009, 249, 692.	2.1	0
347	Thromboangiitis obliterans and the inherited thrombophilias: does an association merit consideration?. Blood Coagulation and Fibrinolysis, 2009, 20, 223-224.	0.5	1
348	Concomitant Occurrence of Kimura Disease and Mycosis Fungoides in a Lebanese Woman: Significance and Response to Rituximab. American Journal of Dermatopathology, 2009, 31, 814-818.	0.3	10
349	Efficacy and Safety of Deferasirox (Exjade®) in $\beta^2$ -Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. Blood, 2009, 114, 4062-4062.	0.6	4
350	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.. Blood, 2009, 114, 5111-5111.	0.6	1
351	COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009029.	0.5	19
352	Frequency distribution of the G/A alleles of the $\beta^2$ -fibrinogen gene in the Lebanese population. Molecular Biology Reports, 2008, 35, 307-311.	1.0	6
353	Factor XIII gene V34L mutation in the Lebanese population: Another unique feature in this community?. Molecular Biology Reports, 2008, 35, 375-378.	1.0	12
354	Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Molecular Biology Reports, 2008, 35, 453-457.	1.0	13
355	Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. Journal of Thrombosis and Thrombolysis, 2008, 26, 138-141.	1.0	20
356	Thrombophilic risk factors among 16 Lebanese patients with cerebral venous and sinus thrombosis. Journal of Thrombosis and Thrombolysis, 2008, 26, 41-43.	1.0	13
357	Hydatid cyst mimicking acute chest syndrome in a sickle thalassemia patient. Annals of Hematology, 2008, 87, 331-332.	0.8	0
358	Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of Hematology, 2008, 87, 545-550.	0.8	42
359	Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Annals of Hematology, 2008, 87, 947-948.	0.8	13
360	Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden. Annals of Hematology, 2008, 87, 1013-1016.	0.8	14

#	ARTICLE	IF	CITATIONS
361	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. <i>Cancer</i> , 2008, 112, 1089-1095.	2.0	68
362	Stroke in thalassemia: A dilemma. <i>American Journal of Hematology</i> , 2008, 83, 343-343.	2.0	18
363	Complications of $\beta^0$ -thalassemia intermedia: A 12-year Lebanese experience. <i>American Journal of Hematology</i> , 2008, 83, 605-606.	2.0	3
364	The Hematologic Manifestations of the Antiphospholipid Syndrome. <i>Blood Reviews</i> , 2008, 22, 187-194.	2.8	103
365	Thalassemia and hypercoagulability. <i>Blood Reviews</i> , 2008, 22, 283-292.	2.8	143
366	Iron and hepatitis C: What can we learn from thalassemia major?. <i>Liver International</i> , 2008, 28, 892-893.	1.9	2
367	Relation Between Iron-Overload Indices, Cardiac Echo-Doppler, and Biochemical Markers in Thalassemia Intermedia. <i>American Journal of Cardiology</i> , 2008, 102, 363-367.	0.7	42
368	Abdominal Manifestations of Multiple Myeloma: A Retrospective Radiologic Overview. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 348-351.	1.4	24
369	Non-Hodgkin's lymphoma in a woman with adult-onset Still's disease: a case report. <i>Journal of Medical Case Reports</i> , 2008, 2, 73.	0.4	15
370	Bilateral Transverse Sinus Thrombosis Secondary to a Homozygous C677T MTHFR Gene Mutation. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 363-365.	1.7	5
371	PULMONARY HYPERTENSION IN $\beta^0$ -THALASSEMIA MAJOR AND THE ROLE OF L-CARNITINE THERAPY. <i>Pediatric Hematology and Oncology</i> , 2008, 25, 734-743.	0.3	30
372	Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood. <i>Pediatrics</i> , 2008, 121, e1426-e1429.	1.0	34
373	Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. <i>Haematologica</i> , 2008, 93, 1584-1586.	1.7	113
374	Successful Treatment of Refractory Skin Manifestations of Systemic Lupus Erythematosus with Rituximab: Report of a Case. <i>Dermatology</i> , 2008, 216, 257-259.	0.9	30
375	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferioxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1 <sup>st</sup> ):1 <sup>st</sup> -15.]. <i>Hemoglobin</i> , 2008, 32, 601-607.	0.4	8
376	High Prevalence of MTHFR Gene A1298C Polymorphism in Lebanon. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 75-80.	1.7	37
377	Elevated levels of circulating procoagulant microparticles in patients with $\beta^0$ -thalassemia intermedia. <i>Haematologica</i> , 2008, 93, 941-942.	1.7	66
378	Pregnancy outcome in patients with $\beta^0$ -thalassemia intermedia at two tertiary care centers, in Beirut and Milan. <i>Haematologica</i> , 2008, 93, 1586-1587.	1.7	54

#	ARTICLE	IF	CITATIONS
379	Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with $\beta^2$ -Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3873-3873.	0.6	12
380	Efficacy and Safety of Deferasirox (Exjade®) in Preventing Cardiac Iron Overload in $\beta^2$ -Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3874-3874.	0.6	9
381	Effect of Deferasirox (Exjade®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. <i>Blood</i> , 2008, 112, 3881-3881.	0.6	14
382	Sickle Cell Disease: New Insights into Pathophysiology and Treatment. <i>Pediatric Annals</i> , 2008, 37, 311-21.	0.3	19
383	Red Blood Cell Enzyme Disorders: An Overview. <i>Pediatric Annals</i> , 2008, 37, 303-10.	0.3	8
384	Is Incentive Spirometry Effective in Preventing Post Surgical Acute Chest Syndrome in Sickle Cell Disease Patients?. <i>Blood</i> , 2008, 112, 4807-4807.	0.6	0
385	Febrile Neutropenia and Hemorrhagic Stroke in a Thalassemia Major Patient. <i>Hemoglobin</i> , 2007, 31, 499-501.	0.4	3
386	Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common $\beta^2$ -thalassemia point mutations and deletions. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 605-10.	1.4	33
387	Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 577-579.	0.5	1
388	Gaucher disease: Different clinical manifestations associated with a rare mutation (R48W) in a Lebanese family. <i>Molecular Genetics and Metabolism</i> , 2007, 91, 402-404.	0.5	5
389	Anticoagulation clinics are needed in developing countries. <i>International Journal of Cardiology</i> , 2007, 115, 410-411.	0.8	1
390	Transforming the Management of Iron Overload. <i>Seminars in Hematology</i> , 2007, 44, S1.	1.8	0
391	Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. <i>Seminars in Hematology</i> , 2007, 44, S2-S6.	1.8	4
392	New Trends in Iron Chelation: Impacting Outcomes. <i>Seminars in Hematology</i> , 2007, 44, S21-S25.	1.8	1
393	Thalidomide and thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 1031-1036.	1.8	108
394	Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: A case report. <i>American Journal of Hematology</i> , 2007, 82, 69-72.	2.0	8
395	Transfusion-transmitted malaria: how vital is the need to screen in non-endemic countries?. <i>Transfusion Medicine</i> , 2007, 17, 415-416.	0.5	2
396	Thrombotic Thrombocytopenic Purpura and Bone Marrow Necrosis Associated with Disseminated Gastric Cancer. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1589-1591.	1.1	13

#	ARTICLE	IF	CITATIONS
397	Gastrointestinal relapse of multiple myeloma: A mimic of lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1194-1196.	0.6	3
398	Ocular Findings Among Thalassemia Patients. <i>American Journal of Ophthalmology</i> , 2006, 142, 704-705.	1.7	36
399	Thalassemia intermedia: Revisited. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 12-20.	0.6	269
400	SAECG parameters and left ventricular chamber sizes: Lesson from anemia conditions in thalassemia major patients. <i>International Journal of Cardiology</i> , 2006, 113, E102-E104.	0.8	6
401	Acute myocardial infarction in a young man: A consequence of inherited thrombophilia and marijuana smoking. <i>Thrombosis and Haemostasis</i> , 2006, 95, 1044.	1.8	9
402	Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in congenital dyserythropoietic anemia type I. <i>Blood</i> , 2006, 107, 4968-4969.	0.6	20
403	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. <i>Thrombosis and Haemostasis</i> , 2006, 96, 488-491.	1.8	281
404	A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 647-650.	0.5	3
405	Hydroxyurea Use in Lebanese Patients With $\beta^2$ -Thalassemia Intermedia. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 107.	0.3	6
406	Compound heterozygosity for factor V and methylenetetrahydrofolate reductase mutations in a patient with Budd-Chiari syndrome.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 782-783.	1.4	0
407	Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1221-1221.	1.4	6
408	Prevalence of factor V Leiden, prothrombin and methylene-tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1114-1118.	0.7	24
409	Massive pulmonary embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with syncope and treated with tenecteplase. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 179-184.	1.0	4
410	Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-cell-thalassemia patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 121-123.	1.0	14
411	Apolipoprotein E Gene Polymorphism and Allele Frequencies in the Lebanese Population. <i>Molecular Biology Reports</i> , 2006, 33, 145-149.	1.0	35
412	Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. <i>Annals of Hematology</i> , 2006, 85, 605-609.	0.8	36
413	Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin. <i>Annals of Hematology</i> , 2006, 85, 743-744.	0.8	12
414	Effect of L-carnitine on the physical fitness of thalassemic patients. <i>Annals of Hematology</i> , 2006, 86, 31-34.	0.8	14

#	ARTICLE	IF	CITATIONS
415	Deep venous thrombosis in a patient with Behçet's disease and homozygous prothrombin (factor II) G20210A mutation on oral contraceptive pills. <i>Rheumatology International</i> , 2006, 26, 758-759.	1.5	5
416	Non-Hodgkin disease in $\beta^2$ -thalassemia major. <i>American Journal of Hematology</i> , 2006, 81, 62-64.	2.0	19
417	$\beta^2$ -thalassemia intermedia and Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2006, 81, 151-151.	2.0	12
418	Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2006, 81, 220-221.	2.0	5
419	Diabetes insipidus and thrombocytosis as the presenting symptoms of acute myeloblastic leukemia with monosomy 7. <i>American Journal of Hematology</i> , 2006, 81, 152-153.	2.0	9
420	Pregnancy in patients with $\beta^2$ -thalassemia intermedia: Outcome of mothers and newborns. <i>American Journal of Hematology</i> , 2006, 81, 499-502.	2.0	46
421	Circulating Microparticles in Lebanese Patients with beta-Thalassemia Intermedia.. <i>Blood</i> , 2006, 108, 1589-1589.	0.6	1
422	Differences in Fetal Hemoglobin Induction in Sickle Cell Disease and beta-Thalassemia.. <i>Blood</i> , 2006, 108, 555-555.	0.6	2
423	Additive Effect of Butyrate and Hemin on Fetal Hemoglobin Induction in Erythroid Cells from Sickle Cell Disease and Beta-Thalassemia.. <i>Blood</i> , 2006, 108, 1224-1224.	0.6	0
424	Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. <i>Thrombosis and Haemostasis</i> , 2006, 96, 488-91.	1.8	86
425	A Clinical Phase II Study of Cisplatin and Vinorelbine (PVn) in Advanced Breast Carcinoma (ABC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 393-398.	0.6	4
426	Moyamoya Syndrome With Intraventricular Hemorrhage in an Adult With Factor V Leiden Mutation. <i>Archives of Neurology</i> , 2005, 62, 1144.	4.9	5
427	Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. <i>British Journal of Haematology</i> , 2005, 130, 644-646.	1.2	63
428	Splenomegaly, pancytopenia and pregnancy: a case report and review of the literature. <i>Journal of Infection</i> , 2005, 51, e273-e275.	1.7	4
429	Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations. <i>Journal of Gastroenterology</i> , 2005, 40, 1002-1003.	2.3	1
430	Venous Thromboembolism in Cancer Patients Referred to the American University of Beirut's Medical Center Secondary to Deep Vein Thrombosis; Occurrence and Risk Factors. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 20, 179-182.	1.0	3
431	Crohn's Disease in Leukemia: Report of a Case, with a Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1950-1950.	1.1	4
432	Safety and Effectiveness of 100 mg/kg/day Deferiprone in Patients with Thalassemia Major: A Two-Year Study. <i>Acta Haematologica</i> , 2005, 114, 146-149.	0.7	37

#	ARTICLE	IF	CITATIONS
433	Iron overload in thalassemia and sickle cell disease. <i>Seminars in Hematology</i> , 2005, 42, S5-S9.	1.8	22
434	The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. <i>Transfusion and Apheresis Science</i> , 2005, 33, 11-17.	0.5	58
435	Deferasirox (Exjade®; ICL670) Treatment of Inadequately Chelated $\beta^2$ -Thalassemia Patients from the Middle East: The ESCALATOR Trial.. <i>Blood</i> , 2005, 106, 3840-3840.	0.6	1
436	Effect of Zoledronic Acid on Bone Mineral Density in Thalassemia-Induced Osteoporosis: Results of a Phase II Clinical Trial.. <i>Blood</i> , 2005, 106, 3826-3826.	0.6	0
437	Thalassemia Major, Intermedia & Sickle-Thal Patients in Lebanon.. <i>Blood</i> , 2005, 106, 3827-3827.	0.6	0
438	Chronic hepatitis C associated with Coombs-positive hemolytic anemia. <i>The Hematology Journal</i> , 2004, 5, 364-366.	2.0	15
439	Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer. <i>Breast</i> , 2004, 13, 421-424.	0.9	2
440	Pregnancy outcome in women with prosthetic heart valves. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1009-1013.	0.7	78
441	Lupus anticoagulant, Factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. <i>Clinical Rheumatology</i> , 2004, 23, 362-3.	1.0	17
442	Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. <i>Annals of Hematology</i> , 2004, 83, 319-321.	0.8	28
443	Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia. <i>American Journal of Hematology</i> , 2004, 77, 374-376.	2.0	8
444	Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review. <i>Journal of Clinical Apheresis</i> , 2004, 19, 5-10.	0.7	33
445	Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. <i>Journal of Clinical Apheresis</i> , 2004, 19, 119-124.	0.7	14
446	Hb H Disease and Multiple Myeloma. <i>Hemoglobin</i> , 2004, 28, 79-82.	0.4	3
447	Improvement of Cardiac Function in Thalassemia major Treated with L-Carnitine. <i>Acta Haematologica</i> , 2004, 111, 143-148.	0.7	29
448	Diamond-Blackfan anemia responding to valproic acid. <i>Blood</i> , 2004, 104, 3415-3415.	0.6	12
449	Heterozygous prothrombin 20210G/A mutation, associated with hyperhomocysteinemia, and homozygous methylenetetrahydrofolate reductase 677C/T mutation, in a patient with portal and mesenteric venous thrombosis. <i>The Hematology Journal</i> , 2004, 5, 540-542.	2.0	11
450	The Incidence of Thromboembolic Events among 8860 Patients with Thalassemia Major and Intermedia in the Mediterranean Area and Iran.. <i>Blood</i> , 2004, 104, 3623-3623.	0.6	4

#	ARTICLE	IF	CITATIONS
451	L-Carnitine and Apoptosis in Thalassemia Major Patients.. Blood, 2004, 104, 3767-3767.	0.6	0
452	Thrombotic thrombocytopenic purpura in a patient with Behçet's disease. Arthritis and Rheumatism, 2003, 48, 1468-1469.	6.7	7
453	Transfusion-associated GVHD: 10 yearsâ€™ experience at the American University of Beirut-Medical Center. Transfusion, 2003, 43, 1672-1676.	0.8	34
454	Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. British Journal of Haematology, 2003, 121, 187-189.	1.2	117
455	Spontaneous intracholecystic bleeding in a patient with von Willebrand's disease. Gastrointestinal Endoscopy, 2003, 58, 809-811.	0.5	7
456	The Codons 8/9 (+G) Mutation Found for the First Time in the Lebanese Population. Hemoglobin, 2003, 27, 1-5.	0.4	2
457	Thalidomide-associated gynecomasty in a patient with multiple myeloma. The Hematology Journal, 2003, 4, 372-372.	2.0	4
458	Title is missing!. Spine, 2003, 28, E245-E249.	1.0	6
459	ANTICARDIOLIPIN ANTIBODIES IN PATIENTS WITH RETINAL VEIN OCCLUSION AND NO RISK FACTORS. Retina, 2003, 23, 486-490.	1.0	26
460	Hypertransfusion: A Successful Method of Treatment in Thalassemia Intermedia Patients With Spinal Cord Compression Secondary to Extramedullary Hematopoiesis. Spine, 2003, 28, E245-E249.	1.0	50
461	Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. The Hematology Journal, 2003, 4, 222-224.	2.0	19
462	High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon. Thrombosis and Haemostasis, 2003, 89, 945-6.	1.8	4
463	SICKLEMIA WITH MULTI-ORGAN FAILURE SYNDROME AND THROMBOTIC THROMBOCYTOPENIC PURPURA. Hemoglobin, 2002, 26, 345-351.	0.4	25
464	PULMONARY THROMBOEMBOLISM IN Î²-THALASSEMIA INTERMEDIA: ARE WE AWARE OF THIS COMPLICATION?. Hemoglobin, 2002, 26, 107-112.	0.4	32
465	Î²-THALASSEMIA INTERMEDIA AND NON-HODGKIN'S LYMPHOMA. Hemoglobin, 2002, 26, 219-225.	0.4	28
466	Catastrophic antiphospholipid syndrome associated with typhoid fever: Comment on the article by Hayem et al. Arthritis and Rheumatism, 2002, 46, 850-850.	6.7	9
467	Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood: Comment on the article by Brunner et al. Arthritis and Rheumatism, 2002, 46, 1410-1410.	6.7	8
468	High Prevalence of Factor V Leiden Mutation among Healthy Individuals and Patients with Deep Venous Thrombosis in Lebanon:. Thrombosis and Haemostasis, 2001, 86, 723-724.	1.8	38

#	ARTICLE	IF	CITATIONS
469	Hughes syndrome associated with varicella infection. <i>Rheumatology International</i> , 2001, 20, 167-168.	1.5	20
470	Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. <i>European Journal of Haematology</i> , 2001, 67, 30-34.	1.1	55
471	EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT WITH $\beta^2$ -THALASSEMIA INTERMEDIA MANIFESTING AS SYMPTOMATIC PLEURAL EFFUSION. <i>Hemoglobin</i> , 2001, 25, 363-368.	0.4	12
472	Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: Case report and literature review. , 2000, 63, 90-93.		11
473	Relation of ferritin levels to pulmonary function in patients with thalassemia major and the acute effects of transfusion. <i>European Journal of Haematology</i> , 2000, 64, 396-400.	1.1	22
474	Autoerythrocyte sensitization(Gardner-Diamond) syndrome. <i>European Journal of Haematology</i> , 2000, 65, 144-147.	1.1	39
475	Interferon alpha is an effective therapy for congenital dyserythropoietic anaemia type I. <i>European Journal of Haematology</i> , 2000, 65, 207-209.	1.1	16
476	Combination Cisplatin-Vinorelbine for Relapsed and Chemotherapy-Pretreated Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 298-302.	0.6	27
477	Thiamine-responsive myelodysplasia. <i>British Journal of Haematology</i> , 1998, 102, 1098-1100.	1.2	50
478	Posttransfusion graft-versus-host disease in two immunocompetent patients. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 862-865.	0.6	10
479	Women with Inherited Bleeding Disorders in Different Cultural Settings. , 0, , 225-233.		0